medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2025, Number 1

<< Back Next >>

Rev Mex Urol 2025; 85 (1)

Epidemiology of prostate Cancer: comparative analysis of major urological cancers

Guzmán EJ, Guzmán SHP, Delgado EI

Language: Spanish
References: 23
Page: 1-10
PDF size: 157.87 Kb.


ABSTRACT

Cancer presents as a leading cause of mortality worldwide, with its incidence exhibiting an upward trend attributable to population aging, the implementation of novel diagnostic tools, and the availability of innovative therapies. In males, prostate cancer stands out as one of the neoplasms with the highest incidence and prevalence, further associated with an elevated mortality rate, excluding skin cancer. A detailed understanding of the incidence, mortality, and particularly, the disease burden of this neoplasm is of paramount relevance, as it allows for the formulation and implementation of measures and strategies in health policies aimed at mitigating the negative impact on both public health and national economies. Globally in 2021, 432,463 deaths due to prostate cancer were recorded, whereas in Mexico the figure reached 8,860. In Mexico and worldwide, prostate cancer is a highly prevalent neoplasm and represents a substantial disease burden. Timely intervention is necessary to mitigate its impact.


REFERENCES

  1. Bray F, Laversanne M, Weiderpass E,Soerjomataram I. The ever-increasingimportance of cancer as a leading causeof premature death worldwide. Cancer. 2021;127(16): 3029–3030. https://doi.org/10.1002/cncr.33587.

  2. Ferlay J, Ervik M, Lam F, Colombet M, MeryL, Piñeros M, et al. Global cancer observatory:cancer today. Lyon: International agency forresearch on cancer. 2020;20182020.

  3. Bray F, Soerjomataram I. The ChangingGlobal Burden of Cancer: Transitions inHuman Development and Implications forCancer Prevention and Control. In: GelbandH, Jha P, Sankaranarayanan R, Horton S (eds.)Cancer: Disease Control Priorities, ThirdEdition (Volume 3). Washington (DC): TheInternational Bank for Reconstruction andDevelopment / The World Bank; 2015. http://www.ncbi.nlm.nih.gov/books/NBK343643/

  4. Tian YQ, Yang JC, Hu JJ, Ding R, Ye DW, ShangJW. Trends and risk factors of global incidence,mortality, and disability of genitourinarycancers from 1990 to 2019: Systematic analysisfor the Global Burden of Disease Study 2019.Frontiers in Public Health. 2023;11: 1119374.https://doi.org/10.3389/fpubh.2023.1119374.

  5. Bray F, Laversanne M, Sung H, Ferlay J,Siegel RL, Soerjomataram I, et al. Globalcancer statistics 2022: GLOBOCAN estimatesof incidence and mortality worldwide for 36cancers in 185 countries. CA: a cancer journalfor clinicians. 2024;74(3): 229–263. https://doi.org/10.3322/caac.21834.

  6. Zi H, He SH, Leng XY, Xu XF, Huang Q, WengH, et al. Global, regional, and national burden ofkidney, bladder, and prostate cancers and theirattributable risk factors, 1990-2019. MilitaryMedical Research. 2021;8(1): 60. https://doi.org/10.1186/s40779-021-00354-z.

  7. Su X, Tao Y, Chen F, Han X, Xue L. Trends in theglobal, regional, and national burden of bladdercancer from 1990 to 2021: an observationalstudy from the global burden of disease study2021. Scientific Reports. 2025;15(1): 7655.https://doi.org/10.1038/s41598-025-92033-5.

  8. Cirillo L, Innocenti S, Becherucci F. Globalepidemiology of kidney cancer. Nephrology,Dialysis, Transplantation: Official Publicationof the European Dialysis and TransplantAssociation - European Renal Association.2024;39(6): 920–928. https://doi.org/10.1093/ndt/gfae036.

  9. Siegel RL, Miller KD, Jemal A. Cancer statistics,2020. CA: a cancer journal for clinicians.2020;70(1): 7–30. https://doi.org/10.3322/caac.21590.

  10. World Health Organization. The GlobalInitiative for Childhood Cancer. World HealthOrganization. 2023. https://www.who.int/initiatives/the-global-initiative-for-childhoodcancer

  11. World Health Organization. SDG Target3.4 | Noncommunicable diseases and mentalhealth: By 2030, reduce by one third prematuremortality from non-communicable diseasesthrough prevention and treatment and promotemental health and well-being. The Global HealthObservatory.2024 https://www.who.int/data/gho/data/themes/topics/indicator-groups/indicator-group-details/GHO/sdg-target-3.4-noncommunicable-diseases-and-mental-health

  12. dos-Santos-Silva I, Gupta S, Orem J, ShulmanLN. Global disparities in access to cancer care.Communications Medicine. 2022;2: 31. https://doi.org/10.1038/s43856-022-00097-5.

  13. Mattiuzzi C, Lippi G. Current CancerEpidemiology. Journal of Epidemiology andGlobal Health. 2019;9(4): 217–222. https://doi.org/10.2991/jegh.k.191008.001.

  14. US Preventive Services Task Force,Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, et al. Screeningfor Prostate Cancer: US Preventive ServicesTask Force Recommendation Statement.JAMA. 2018;319(18): 1901–1913. https://doi.org/10.1001/jama.2018.3710.

  15. American cancer Society (apellido). KeyStatistics for Prostate Cancer. American cancerSociety. 2025.

  16. International Agency for Research on Cancer.Cancer Today. 2025. https://gco.iarc.who.int/today/

  17. James ND, Tannock I, N’Dow J, Feng F, GillessenS, Ali SA, et al. The Lancet Commission onprostate cancer: planning for the surge in cases.Lancet (London, England). 2024;403(10437):1683–1722. https://doi.org/10.1016/S0140-6736(24)00651-2.

  18. Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC,Brawley O, et al. Prostate Cancer Incidenceand PSA Testing Patterns in Relation toUSPSTF Screening Recommendations. JAMA.2015;314(19): 2054–2061. https://doi.org/10.1001/jama.2015.14905.

  19. Moyer VA, U.S. Preventive Services Task Force.Screening for prostate cancer: U.S. PreventiveServices Task Force recommendation statement.Annals of Internal Medicine. 2012;157(2): 120–134. https://doi.org/10.7326/0003-4819-157-2-201207170-00459.

  20. Borregales LD, DeMeo G, Gu X, Cheng E,Dudley V, Schaeffer EM, et al. Grade Migrationof Prostate Cancer in the United States Duringthe Last Decade. Journal of the National CancerInstitute. 2022;114(7): 1012–1019. https://doi.org/10.1093/jnci/djac066.

  21. Bergengren O, Pekala KR, Matsoukas K,Fainberg J, Mungovan SF, Bratt O, et al. 2022Update on Prostate Cancer Epidemiology andRisk Factors—A Systematic Review. Europeanurology. 2023;84(2): 191–206. https://doi.org/10.1016/j.eururo.2023.04.021.

  22. Zlotta AR, Egawa S, Pushkar D, Govorov A,Kimura T, Kido M, et al. Prevalence of prostatecancer on autopsy: cross-sectional study onunscreened Caucasian and Asian men. Journalof the National Cancer Institute. 2013;105(14):1050–1058. https://doi.org/10.1093/jnci/djt151.

  23. Johns LE, Houlston RS. A systematic review andmeta-analysis of familial prostate cancer risk.BJU international. 2003;91(9): 789–794. https://doi.org/10.1046/j.1464-410x.2003.04232.x.




2020     |     www.medigraphic.com